MTOR and sarcoma: Several approaches targeting hypoxia in sarcoma cells have been explored, including the use of bioreductive prodrugs that are converted to cytotoxins under hypoxic conditions, developing inhibitors of HIF1 expression and activity, targeting oncogenic pathways (mTOR) regulating HIF1 expression, and targeting specific HIF downstream pathways [63].